Skip to content
-
Media

News & Insights

When you have a passion for innovation and an aspiration to improve the lives of people with skin diseases, you are going to make some headlines. Learn about our latest news below.

05/03/25 Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors

 

27/02/25 LEO Pharma Meets Primary Endpoint in Phase 3 DELTA China Trial with Anzupgo® (delgocitinib) Cream in Chinese Patients with Moderate to Severe Chronic Hand Eczema (CHE)

 

26/02/25 LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation

 

In case you missed it

 

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Our performance and results

2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly improved EBITDA.
Read our 2024 Annual Report

Images

Explore our media library so you can put faces to names and see our state-of-the-art production facilities and offices.
Go to Image Library

Useful information

 

  • Fact sheet
    A concise summary of LEO Pharma’s key information and achievements. Expect clear, straightforward data and essential insights.
  • Global Leadership Team
    Get to know our top management team, featuring their expertise, accomplishments, and pivotal roles in driving LEO Pharma's success.

 

MEDIA INQUIRIES
Jeppe Ilkjaer

Jeppe Ilkjaer

Head of Media
Tel: +45 30502014
Get in touch
Anders

Anders Monrad Rendtorff

SVP, Head of Corporate Communications
Get in touch

Our press releases are intended for the media

To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request.. For updated information about clinical trials, please visit https://clinicaltrials.gov/ https://clinicaltrials.gov/.

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com